BLTE BELITE BIO INC revenue, earnings and financials
For the fiscal year ended December 2025 revenue was n/a.
BLTE annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$84.2M, net income −$77.6M (margin n/a), EPS −$2.31
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$40.0M, net income −$36.1M (margin n/a), EPS −$1.18
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$31.7M, net income −$31.6M (margin n/a), EPS −$1.19
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$12.8M, net income −$12.6M (margin n/a), EPS −$0.63
- Fiscal year ended Dec 2021: revenue n/a, gross profit n/a, operating income −$9.80M, net income −$9.67M (margin n/a), EPS −$1.01
BLTE cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$37.0M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$29.2M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$29.8M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$11.5M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$7.47M, share buybacks n/a
BLTE balance sheet
- Dec 31, 2025: cash $353M, total assets $781M, total liabilities $10.1M, shareholders' equity $770M
- Dec 31, 2024: cash $31.7M, total assets $152M, total liabilities $6.31M, shareholders' equity $146M
- Dec 31, 2023: cash $88.2M, total assets $94.6M, total liabilities $4.21M, shareholders' equity $90.4M
- Dec 31, 2022: cash $42.1M, total assets $44.3M, total liabilities $2.77M, shareholders' equity $41.5M
- Dec 31, 2021: cash $17.3M, total assets $18.3M, total liabilities $1.64M, shareholders' equity −$15.1M
Is BLTE profitable?
No. BELITE BIO INC lost $77.6M in its latest fiscal year.